- Stocks
- Pharma & Healthcare
- Lasa Supergenerics
Lasa Supergenerics share price
NSE: LASAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Lasa Supergenerics at a glance
With a market capitalisation of ₹37 Cr, it ranks 3259th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −17.6% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was −₹0 Cr (−100.3% year on year) and net profit −₹4 Cr, on a standalone basis. Promoters held 53.65% of the company as of 31 Mar 2026; 20.66% of promoter shares were pledged.
Key numbers
- Market cap
- ₹37 CrRank 3259 on NSE
- Price to book
- 1.01×FY25
- EPS (TTM)
- −₹6.81to Q4 FY26
- ROE
- −17.6%FY25
- ROCE
- −1.2%FY25
- Debt to equity
- 0FY25
- Net profit margin
- −10.4%FY25
- Book value / share
- ₹16.71FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Lasa Supergenerics quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹31 Cr | ₹39 Cr | ₹33 Cr | ₹39 Cr | ₹20 Cr | ₹3 Cr | ₹2 Cr | −₹0 Cr |
| Revenue YoY | +0.9% | +62.1% | +24.1% | +71.5% | −35.1% | −92.2% | −93.3% | −100.3% |
| Net profit | −₹3 Cr | −₹3 Cr | ₹5 Cr | −₹14 Cr | −₹21 Cr | −₹6 Cr | −₹3 Cr | −₹4 Cr |
| Net profit YoY | — | — | — | — | — | — | −146.4% | — |
| Net margin | −8.9% | −8.2% | 16.6% | −36.5% | −105.5% | −204.2% | −115.9% | 3,200.0% |
| EPS | −₹0.55 | −₹0.64 | ₹1.10 | −₹2.85 | −₹4.22 | −₹1.25 | −₹0.51 | −₹0.83 |
Lasa Supergenerics financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹167 Cr | ₹202 Cr | ₹137 Cr | ₹130 Cr | ₹104 Cr | ₹142 Cr |
| Operating profit | ₹5 Cr | ₹29 Cr | ₹2 Cr | −₹22 Cr | −₹10 Cr | −₹4 Cr |
| Net profit | ₹4 Cr | ₹23 Cr | −₹5 Cr | −₹39 Cr | −₹22 Cr | −₹15 Cr |
| EPS (₹) | ₹1.26 | ₹5.60 | −₹1.30 | −₹7.71 | −₹4.34 | −₹2.95 |
| Cash from operations | ₹14 Cr | ₹41 Cr | ₹10 Cr | −₹17 Cr | ₹2 Cr | −₹3 Cr |
| Total debt | ₹14 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹141 Cr | ₹159 Cr | ₹149 Cr | ₹118 Cr | ₹97 Cr | ₹84 Cr |
Lasa Supergenerics shareholding pattern
| Holder | 31 Dec 2024 | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% |
| Non-institutions | 46.35% | 46.35% | 46.35% | 46.35% | 46.35% | 46.35% |
| Promoter shares pledged | 20.66% | 20.66% | 20.66% | 20.66% | 20.66% | 20.66% |
Lasa Supergenerics vs peers
The listed Pharma & Healthcare companies nearest to Lasa Supergenerics by market capitalisation.
Ask anything about Lasa Supergenerics
Pivot answers on the live chart with evidence you can check, and tests strategies against LASA's own history. Try: “Why has LASA moved over the last three months?” · “Backtest a 50-day moving-average crossover on LASA over five years” · “Compare LASA with SANDUPHQ on margins and valuation”
Frequently asked questions about Lasa Supergenerics
What is the market cap of Lasa Supergenerics?
Lasa Supergenerics' market capitalisation is ₹37 Cr (₹37 Cr) at the 22 Oct 2026 close, ranking 3259th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Lasa Supergenerics?
Return on equity was −17.6% in FY25 and return on capital employed was −1.2% in FY25 (standalone figures).
Is Lasa Supergenerics a debt-free company?
Lasa Supergenerics is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Lasa Supergenerics' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Lasa Supergenerics reported revenue of −₹0 Cr, −100.3% year on year, and net profit of −₹4 Cr.
What is the shareholding pattern of Lasa Supergenerics?
As of 31 Mar 2026: promoters 53.65%, non-institutions 46.35%. 20.66% of promoter shares were pledged.
Who are Lasa Supergenerics' competitors?
The listed Pharma & Healthcare companies closest to Lasa Supergenerics by market cap are Sandu Pharma, Medicamen Organ, Roopa Ind, JFL Life Scienc, Chandra Bhagat and Sharma East Ind.
Is Lasa Supergenerics a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Lasa Supergenerics' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LASA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with L · all NSE stocks · this page as text